Asia Pacific Diabetes Care Devices Market Forecast 2025–2034

Asia Pacific Diabetes Care Devices Market - By Product, By End Use - Forecast, 2025 - 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Regional/country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional trends

2.2.2&nbsp;&nbsp;&nbsp; Product trends

2.2.3&nbsp;&nbsp;&nbsp; End use trends

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.1.1&nbsp;&nbsp;&nbsp; Supplier landscape

3.1.2&nbsp;&nbsp;&nbsp; Value addition at each stage

3.1.3&nbsp;&nbsp;&nbsp; Factor affecting the value chain

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Escalating diabetes prevalence across Asia Pacific

3.2.1.2&nbsp;&nbsp;&nbsp; Advancement in technological in diabetes care devices

3.2.1.3&nbsp;&nbsp;&nbsp; Increased public and private sector investments for diabetes care

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of diabetes care devices

3.2.2.2&nbsp;&nbsp;&nbsp; Stringent regulatory landscape

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Expansion in emerging Asia Pacific markets

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.4.1&nbsp;&nbsp;&nbsp; China

3.4.2&nbsp;&nbsp;&nbsp; Japan

3.4.3&nbsp;&nbsp;&nbsp; India

3.5&nbsp;&nbsp;&nbsp; Technological advancements

3.5.1&nbsp;&nbsp;&nbsp; Current technological trends

3.5.2&nbsp;&nbsp;&nbsp; Emerging technologies

3.6&nbsp;&nbsp;&nbsp; Diabetes epidemiology and disease burden analysis

3.6.1&nbsp;&nbsp;&nbsp; Regional diabetes prevalence trends

3.6.2&nbsp;&nbsp;&nbsp; Gestational diabetes prevalence

3.6.3&nbsp;&nbsp;&nbsp; Complication rates and healthcare costs

3.7&nbsp;&nbsp;&nbsp; Patent landscape analysis for diabetes device innovations

3.8&nbsp;&nbsp;&nbsp; Clinical trial pipeline assessment for emerging technologies

3.9&nbsp;&nbsp;&nbsp; Supply chain and distribution analysis

3.10&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.11&nbsp;&nbsp;&nbsp; Pricing analysis, 2024

3.12&nbsp;&nbsp;&nbsp; Future market trends

3.13&nbsp;&nbsp;&nbsp; Gap analysis

3.14&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.15&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Key developments

4.6.1&nbsp;&nbsp;&nbsp; Mergers and acquisitions

4.6.2&nbsp;&nbsp;&nbsp; Partnerships and collaborations

4.6.3&nbsp;&nbsp;&nbsp; New product launches

4.6.4&nbsp;&nbsp;&nbsp; Expansion plans

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Device

5.2.1&nbsp;&nbsp;&nbsp; Blood glucose monitoring devices

5.2.1.1&nbsp;&nbsp;&nbsp; Self-monitoring blood glucose meters

5.2.1.2&nbsp;&nbsp;&nbsp; Continuous glucose monitors

5.2.2&nbsp;&nbsp;&nbsp; Insulin delivery devices

5.2.2.1&nbsp;&nbsp;&nbsp; Insulin pumps

5.2.2.1.1&nbsp;&nbsp;&nbsp; Tubed pumps

5.2.2.1.2&nbsp;&nbsp;&nbsp; Tubeless pumps

5.2.2.2&nbsp;&nbsp;&nbsp; Pens

5.2.2.2.1&nbsp;&nbsp;&nbsp; Reusable

5.2.2.2.2&nbsp;&nbsp;&nbsp; Disposable

5.2.3&nbsp;&nbsp;&nbsp; Other insulin delivery devices

5.3&nbsp;&nbsp;&nbsp; Consumables

5.3.1&nbsp;&nbsp;&nbsp; Testing strips

5.3.2&nbsp;&nbsp;&nbsp; Lancets

5.3.3&nbsp;&nbsp;&nbsp; Pen needles

5.3.3.1&nbsp;&nbsp;&nbsp; Standard

5.3.3.2&nbsp;&nbsp;&nbsp; Safety

5.3.4&nbsp;&nbsp;&nbsp; Syringes

5.3.5&nbsp;&nbsp;&nbsp; Insulin pumps consumables

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Hospital

6.3&nbsp;&nbsp;&nbsp; Ambulatory surgical centres

6.4&nbsp;&nbsp;&nbsp; Diagnostic centres

6.5&nbsp;&nbsp;&nbsp; Homecare

6.6&nbsp;&nbsp;&nbsp; Other end use

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Country, 2021 - 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Japan

7.3&nbsp;&nbsp;&nbsp; China

7.4&nbsp;&nbsp;&nbsp; India

7.5&nbsp;&nbsp;&nbsp; Australia

7.6&nbsp;&nbsp;&nbsp; South Korea

7.7&nbsp;&nbsp;&nbsp; Taiwan

7.8&nbsp;&nbsp;&nbsp; Indonesia

7.9&nbsp;&nbsp;&nbsp; Vietnam

Chapter 8&nbsp;&nbsp;&nbsp;Company Profiles

8.1&nbsp;&nbsp;&nbsp; Abbott Laboratories

8.2&nbsp;&nbsp;&nbsp; ARKRAY

8.3&nbsp;&nbsp;&nbsp; Ascensia Diabetes Care

8.4&nbsp;&nbsp;&nbsp; B. Braun Melsungen

8.5&nbsp;&nbsp;&nbsp; Becton, Dickinson and Company

8.6&nbsp;&nbsp;&nbsp; Bionime

8.7&nbsp;&nbsp;&nbsp; Dr. Reddy&rsquo;s Laboratories

8.8&nbsp;&nbsp;&nbsp; Eli Lilly and Company

8.9&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche

8.10&nbsp;&nbsp;&nbsp; Insulet

8.11&nbsp;&nbsp;&nbsp; Medtronic

8.12&nbsp;&nbsp;&nbsp; Nova Biomedical

8.13&nbsp;&nbsp;&nbsp; Novo Nordisk

8.14&nbsp;&nbsp;&nbsp; Platinum Equity Advisors

8.15&nbsp;&nbsp;&nbsp; Sanofi

8.16&nbsp;&nbsp;&nbsp; Sinocare

Asia Pacific Diabetes Care Devices Market

Inquiry Before Buying